• EBITDA margin performance: Normalized EBITDA margins stood at around 26% for the full year and 25.6% to 25.7% for the quarter. US operations maintained quarter-on-quarter growth despite the high prior-year base from Revlimid sales ending.
• US pipeline expansion: Following the launch of over 30 products last year, the company plans to introduce 40-plus new products in the US market this year, including drugs with semi- to single-use exclusivity.
• Specialty business growth: The rare disease business under Sentinel Therapeutics has scaled up and turned profitable, alongside growth in the 505(b)(2) Sitagliptin franchise, the addition of the Beze acquisition, and a planned supportive oncology launch by year-end.
• Foreign exchange impact: Rupee depreciation creates a net foreign exchange gain because the company is a net exporter with a large share of revenue in US dollars, helping offset rising transportation and input material costs.